middle.news
Actinogen Surpasses 100 Patients in Alzheimer’s Trial, Eyes January Interim Analysis
9:04am on Wednesday 30th of July, 2025 AEST
•
Biotechnology
Read Story
Actinogen Surpasses 100 Patients in Alzheimer’s Trial, Eyes January Interim Analysis
9:04am on Wednesday 30th of July, 2025 AEST
Key Points
XanaMIA trial surpasses 100 enrolled participants
Interim safety and efficacy analysis scheduled for January 2026
$13.8 million non-dilutive R&D tax incentive funding secured
Manufacturing scale-up batch of Xanamem completed
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ACW
OPEN ARTICLE